Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet. The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-approved medication in India for the treatment of Covid-19, it said in a statement. The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said.
“This drug was already being used in Japan for influenza. They have been using it in COVID-19 patients also. Even China was using it and Russia had also given permission in May to use it. Antiviral drug like Remdesivir and Favipiravir are not specific to COVID-19 but were being used for influenza, “said Dr Vikas Maurya, Director, Department of Pulmonology and Sleep Disorders, Fortis Hospital, Shalimar Bagh.
Glenmark Pharmaceuticals was the first company in India to initiate phase three clincal trials on Favipiravir for COVID-19 patients in India.
For More Information Visit www.glenmarkpharma.com
Glenmark-becomes-the-first-pharmaceut-cal-company-in-India-to-receive
Glenmark Launches Covid-19 Drug Favipiravir At Rs 103 per Tablet
